Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 51.80
-0.70 (-1.33%)
At close: Mar 3, 2025
Navana Pharmaceuticals Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Net Income | 421.76 | 404.63 | 356.94 | 274 | 202.29 | 137.4 |
| Depreciation & Amortization | 223.98 | 214.96 | 210.41 | 165.84 | 87.27 | 68.81 |
| Other Amortization | 0.33 | 0.22 | - | 0.22 | 0.11 | - |
| Loss (Gain) From Sale of Assets | -1.18 | -1.18 | - | -0.47 | 0 | - |
| Loss (Gain) From Sale of Investments | -134.42 | -123.14 | 46.8 | -82.9 | - | -19.68 |
| Other Operating Activities | 173.46 | 341.5 | 134.99 | 147.08 | 75.47 | 9.12 |
| Change in Accounts Receivable | 90.69 | -218.89 | -253.42 | -84.93 | -74.38 | 28.94 |
| Change in Inventory | -606.69 | -620.6 | -344.07 | -200.76 | -95.7 | -34.74 |
| Change in Accounts Payable | 330.08 | 332.93 | 152.22 | 79.44 | 8.78 | 3.97 |
| Change in Other Net Operating Assets | 455.43 | 376.88 | -110.13 | -98.16 | -82.11 | 7.69 |
| Operating Cash Flow | 953.44 | 707.3 | 193.74 | 199.36 | 121.75 | 201.5 |
| Operating Cash Flow Growth | 360.10% | 265.07% | -2.82% | 63.74% | -39.58% | - |
| Capital Expenditures | -1,001 | -1,332 | -1,598 | -1,359 | -520.75 | -19.71 |
| Sale of Property, Plant & Equipment | 1.48 | 1.48 | - | - | - | - |
| Investment in Securities | 27.08 | 13.48 | -2.33 | -171.48 | 53.65 | - |
| Other Investing Activities | 1.3 | 1.14 | 2.79 | 3.26 | -1.17 | - |
| Investing Cash Flow | -970.84 | -1,316 | -1,598 | -1,527 | -468.28 | -19.71 |
| Short-Term Debt Issued | - | 942.14 | 1,384 | 1,551 | 360.66 | - |
| Long-Term Debt Issued | - | 121.97 | - | 17.74 | 93.09 | - |
| Total Debt Issued | 688.26 | 1,064 | 1,384 | 1,569 | 453.75 | - |
| Short-Term Debt Repaid | - | - | - | - | - | -15.39 |
| Long-Term Debt Repaid | - | -16.26 | -66.46 | -45.83 | -72.02 | -135.3 |
| Total Debt Repaid | -265.58 | -16.26 | -66.46 | -45.83 | -72.02 | -150.69 |
| Net Debt Issued (Repaid) | 422.68 | 1,048 | 1,318 | 1,523 | 381.73 | -150.69 |
| Issuance of Common Stock | - | - | 750 | - | - | - |
| Common Dividends Paid | -137.31 | -136.88 | -113.15 | - | - | - |
| Other Financing Activities | -304.57 | -475.12 | -175.98 | -154.73 | -64.15 | - |
| Financing Cash Flow | -19.2 | 435.84 | 1,778 | 1,368 | 317.59 | -150.69 |
| Foreign Exchange Rate Adjustments | 3.81 | - | - | 0.05 | - | 0 |
| Miscellaneous Cash Flow Adjustments | -0 | - | 0.05 | -0 | - | 0 |
| Net Cash Flow | -32.79 | -173.16 | 374.5 | 40.65 | -28.94 | 31.1 |
| Free Cash Flow | -47.27 | -625.1 | -1,404 | -1,160 | -399 | 181.8 |
| Free Cash Flow Margin | -0.59% | -9.06% | -24.61% | -24.37% | -11.06% | 5.77% |
| Free Cash Flow Per Share | -0.44 | -5.82 | -14.13 | -14.45 | -4.97 | 2.27 |
| Cash Interest Paid | 304.57 | 475.12 | 157.9 | 142.83 | 64.15 | 79.11 |
| Cash Income Tax Paid | 146.66 | 131.47 | 101 | 110.27 | 88.79 | 72.77 |
| Levered Free Cash Flow | -485.4 | -1,180 | -2,393 | -1,836 | -461.76 | - |
| Unlevered Free Cash Flow | -70.26 | -889.89 | -2,246 | -1,711 | -414.77 | - |
| Change in Net Working Capital | 73.25 | 392.56 | 1,331 | 873.8 | 199.27 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.